APO Research
Talk to an analyst

APO RESEARCH · REPORT

Diabetic Neuropathic Pain Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Diabetic Neuropathic Pain Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

26 December 2025195 pages

Choose your research edition.

Industry ResearchDiabetic Neuropathic Pain Drug Industry Research Report 2026138 pages · $2,950 USDIndustry Growth & TrendsGlobal Diabetic Neuropathic Pain Drug Industry Growth and Trends Forecast to 2032116 pages · $3,450 USDMarket StructureGlobal Diabetic Neuropathic Pain Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Diabetic Neuropathic Pain Drug Market Outlook and Growth Opportunities 2026209 pages · $4,250 USDMarket Analysis & ForecastGlobal Diabetic Neuropathic Pain Drug Market Analysis and Forecast 2026-2032202 pages · $4,950 USD

Market perspective

The global Diabetic Neuropathic Pain Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Diabetic Neuropathic Pain Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Diabetic Neuropathic Pain Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Diabetic Neuropathic Pain Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Diabetic Neuropathic Pain Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Diabetic Neuropathic Pain Drug include Eli Lilly and Company, Astellas Pharma Inc., AstraZeneca Plc, Theravasc, Inc., Sphaera Pharma Pvt. Ltd., Relmada Therapeutics, Inc., RAPID Pharmaceuticals AG, Pharmaleads and Novaremed, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Diabetic Neuropathic Pain Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Diabetic Neuropathic Pain Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Diabetic Neuropathic Pain Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Diabetic Neuropathic Pain Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Diabetic Neuropathic Pain Drug Segment by Company

Eli Lilly and Company

Astellas Pharma Inc.

AstraZeneca Plc

Theravasc, Inc.

Sphaera Pharma Pvt. Ltd.

Relmada Therapeutics, Inc.

RAPID Pharmaceuticals AG

Pharmaleads

Novaremed

Mertiva AB

Lohocla Research Corporation

Laboratorios Del Dr. Esteve S.A.

Immune Pharmaceuticals Inc.

Hydra Biosciences, Inc.

Glenmark Pharmaceuticals Ltd.

Dong-A Socio Group

Daiichi Sankyo Company, Limited

Boehringer Ingelheim GmbH

BioDelivery Sciences International, Inc.

Diabetic Neuropathic Pain Drug Segment by Type

AZD-5213

E-52862

GERPOOI

GRC-17536

Filgrastim

Duloxetine Hydrochloride DR

Clonidine Hydrochloride

Others

Diabetic Neuropathic Pain Drug Segment by Application

Clinic

Hospital

Others

Diabetic Neuropathic Pain Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Diabetic Neuropathic Pain Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Diabetic Neuropathic Pain Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Diabetic Neuropathic Pain Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Diabetic Neuropathic Pain Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Diabetic Neuropathic Pain Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Diabetic Neuropathic Pain Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Diabetic Neuropathic Pain Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Diabetic Neuropathic Pain Drug Industry Trends Table 2. Diabetic Neuropathic Pain Drug Industry Drivers Table 3. Diabetic Neuropathic Pain Drug Industry Opportunities and Challenges Table 4. Diabetic Neuropathic Pain Drug Industry Restraints Table 5. Global Diabetic Neuropathic Pain Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Diabetic Neuropathic Pain Drug Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Diabetic Neuropathic Pain Drug Sales by Manufacturers (W Units) & (2021-2026) Table 8. Global Diabetic Neuropathic Pain Drug Sales Market Share by Manufacturers Table 9. Global Diabetic Neuropathic Pain Drug Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Diabetic Neuropathic Pain Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Diabetic Neuropathic Pain Drug Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Diabetic Neuropathic Pain Drug Manufacturers, Product Type & Application Table 13. Global Diabetic Neuropathic Pain Drug Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Diabetic Neuropathic Pain Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of AZD-5213 Table 17. Major Manufacturers of E-52862 Table 18. Major Manufacturers of GERPOOI Table 19. Major Manufacturers of GRC-17536 Table 20. Major Manufacturers of Filgrastim Table 21. Major Manufacturers of Duloxetine Hydrochloride DR Table 22. Major Manufacturers of Clonidine Hydrochloride Table 23. Major Manufacturers of Others Table 24. Global Diabetic Neuropathic Pain Drug Sales by Type 2021 VS 2025 VS 2032 (W Units) Table 25. Global Diabetic Neuropathic Pain Drug Sales by Type (2021-2026) & (W Units) Table 26. Global Diabetic Neuropathic Pain Drug Sales by Type (2027-2032) & (W Units) Table 27. Global Diabetic Neuropathic Pain Drug Sales Market Share by Type (2021-2026) Table 28. Global Diabetic Neuropathic Pain Drug Sales Market Share by Type (2027-2032) Table 29. Global Diabetic Neuropathic Pain Drug Revenue by Type 2021 VS 2025 VS 2032 (W Units) Table 30. Global Diabetic Neuropathic Pain Drug Revenue by Type (2021-2026) & (W Units) Table 31. Global Diabetic Neuropathic Pain Drug Revenue by Type (2027-2032) & (W Units) Table 32. Global Diabetic Neuropathic Pain Drug Revenue Market Share by Type (2021-2026) Table 33. Global Diabetic Neuropathic Pain Drug Revenue Market Share by Type (2027-2032) Table 34. Major Manufacturers of Clinic Table 35. Major Manufacturers of Hospital Table 36. Major Manufacturers of Others Table 37. Global Diabetic Neuropathic Pain Drug Sales by Application 2021 VS 2025 VS 2032 (W Units) Table 38. Global Diabetic Neuropathic Pain Drug Sales by Application (2021-2026) & (W Units) Table 39. Global Diabetic Neuropathic Pain Drug Sales by Application (2027-2032) & (W Units) Table 40. Global Diabetic Neuropathic Pain Drug Sales Market Share by Application (2021-2026) Table 41. Global Diabetic Neuropathic Pain Drug Sales Market Share by Application (2027-2032) Table 42. Global Diabetic Neuropathic Pain Drug Revenue by Application 2021 VS 2025 VS 2032 (W Units) Table 43. Global Diabetic Neuropathic Pain Drug Revenue by Application (2021-2026) & (W Units) Table 44. Global Diabetic Neuropathic Pain Drug Revenue by Application (2027-2032) & (W Units) Table 45. Global Diabetic Neuropathic Pain Drug Revenue Market Share by Application (2021-2026) Table 46. Global Diabetic Neuropathic Pain Drug Revenue Market Share by Application (2027-2032) Table 47. Global Diabetic Neuropathic Pain Drug Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 48. Global Diabetic Neuropathic Pain Drug Sales by Region (2021-2026) & (W Units) Table 49. Global Diabetic Neuropathic Pain Drug Sales Market Share by Region (2021-2026) Table 50. Global Diabetic Neuropathic Pain Drug Sales Forecasted by Region (2027-2032) & (W Units) Table 51. Global Diabetic Neuropathic Pain Drug Sales Forecasted Market Share by Region (2027-2032) Table 52. North America Diabetic Neuropathic Pain Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 53. North America Diabetic Neuropathic Pain Drug Sales by Country (2021-2026) & (W Units) Table 54. North America Diabetic Neuropathic Pain Drug Sales by Country (2027-2032) & (W Units) Table 55. Europe Diabetic Neuropathic Pain Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 56. Europe Diabetic Neuropathic Pain Drug Sales by Country (2021-2026) & (W Units) Table 57. Europe Diabetic Neuropathic Pain Drug Sales by Country (2027-2032) & (W Units) Table 58. Asia Pacific Diabetic Neuropathic Pain Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 59. Asia Pacific Diabetic Neuropathic Pain Drug Sales by Country (2021-2026) & (W Units) Table 60. Asia Pacific Diabetic Neuropathic Pain Drug Sales by Country (2027-2032) & (W Units) Table 61. South America, Middle East and Africa Diabetic Neuropathic Pain Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 62. South America, Middle East and Africa Diabetic Neuropathic Pain Drug Sales by Country (2021-2026) & (W Units) Table 63. South America, Middle East and Africa Diabetic Neuropathic Pain Drug Sales by Country (2027-2032) & (W Units) Table 64. Global Diabetic Neuropathic Pain Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 65. Global Diabetic Neuropathic Pain Drug Revenue by Region (2021-2026) & (US$ Million) Table 66. Global Diabetic Neuropathic Pain Drug Revenue by Region (2027-2032) & (US$ Million) Table 67. Global Diabetic Neuropathic Pain Drug Revenue Market Share by Region (2021-2026) Table 68. Global Diabetic Neuropathic Pain Drug Revenue Market Share by Region (2027-2032) Table 69. Eli Lilly and Company Company Information Table 70. Eli Lilly and Company Business Overview Table 71. Eli Lilly and Company Diabetic Neuropathic Pain Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Eli Lilly and Company Diabetic Neuropathic Pain Drug Product Portfolio Table 73. Eli Lilly and Company Recent Development Table 74. Astellas Pharma Inc. Company Information Table 75. Astellas Pharma Inc. Business Overview Table 76. Astellas Pharma Inc. Diabetic Neuropathic Pain Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Astellas Pharma Inc. Diabetic Neuropathic Pain Drug Product Portfolio Table 78. Astellas Pharma Inc. Recent Development Table 79. AstraZeneca Plc Company Information Table 80. AstraZeneca Plc Business Overview Table 81. AstraZeneca Plc Diabetic Neuropathic Pain Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. AstraZeneca Plc Diabetic Neuropathic Pain Drug Product Portfolio Table 83. AstraZeneca Plc Recent Development Table 84. Theravasc, Inc. Company Information Table 85. Theravasc, Inc. Business Overview Table 86. Theravasc, Inc. Diabetic Neuropathic Pain Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Theravasc, Inc. Diabetic Neuropathic Pain Drug Product Portfolio Table 88. Theravasc, Inc. Recent Development Table 89. Sphaera Pharma Pvt. Ltd. Company Information Table 90. Sphaera Pharma Pvt. Ltd. Business Overview Table 91. Sphaera Pharma Pvt. Ltd. Diabetic Neuropathic Pain Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Sphaera Pharma Pvt. Ltd. Diabetic Neuropathic Pain Drug Product Portfolio Table 93. Sphaera Pharma Pvt. Ltd. Recent Development Table 94. Relmada Therapeutics, Inc. Company Information Table 95. Relmada Therapeutics, Inc. Business Overview Table 96. Relmada Therapeutics, Inc. Diabetic Neuropathic Pain Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Relmada Therapeutics, Inc. Diabetic Neuropathic Pain Drug Product Portfolio Table 98. Relmada Therapeutics, Inc. Recent Development Table 99. RAPID Pharmaceuticals AG Company Information Table 100. RAPID Pharmaceuticals AG Business Overview Table 101. RAPID Pharmaceuticals AG Diabetic Neuropathic Pain Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. RAPID Pharmaceuticals AG Diabetic Neuropathic Pain Drug Product Portfolio Table 103. RAPID Pharmaceuticals AG Recent Development Table 104. Pharmaleads Company Information Table 105. Pharmaleads Business Overview Table 106. Pharmaleads Diabetic Neuropathic Pain Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. Pharmaleads Diabetic Neuropathic Pain Drug Product Portfolio Table 108. Pharmaleads Recent Development Table 109. Novaremed Company Information Table 110. Novaremed Business Overview Table 111. Novaremed Diabetic Neuropathic Pain Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 112. Novaremed Diabetic Neuropathic Pain Drug Product Portfolio Table 113. Novaremed Recent Development Table 114. Mertiva AB Company Information Table 115. Mertiva AB Business Overview Table 116. Mertiva AB Diabetic Neuropathic Pain Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 117. Mertiva AB Diabetic Neuropathic Pain Drug Product Portfolio Table 118. Mertiva AB Recent Development Table 119. Lohocla Research Corporation Company Information Table 120. Lohocla Research Corporation Business Overview Table 121. Lohocla Research Corporation Diabetic Neuropathic Pain Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 122. Lohocla Research Corporation Diabetic Neuropathic Pain Drug Product Portfolio Table 123. Lohocla Research Corporation Recent Development Table 124. Laboratorios Del Dr. Esteve S.A. Company Information Table 125. Laboratorios Del Dr. Esteve S.A. Business Overview Table 126. Laboratorios Del Dr. Esteve S.A. Diabetic Neuropathic Pain Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 127. Laboratorios Del Dr. Esteve S.A. Diabetic Neuropathic Pain Drug Product Portfolio Table 128. Laboratorios Del Dr. Esteve S.A. Recent Development Table 129. Immune Pharmaceuticals Inc. Company Information Table 130. Immune Pharmaceuticals Inc. Business Overview Table 131. Immune Pharmaceuticals Inc. Diabetic Neuropathic Pain Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 132. Immune Pharmaceuticals Inc. Diabetic Neuropathic Pain Drug Product Portfolio Table 133. Immune Pharmaceuticals Inc. Recent Development Table 134. Hydra Biosciences, Inc. Company Information Table 135. Hydra Biosciences, Inc. Business Overview Table 136. Hydra Biosciences, Inc. Diabetic Neuropathic Pain Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 137. Hydra Biosciences, Inc. Diabetic Neuropathic Pain Drug Product Portfolio Table 138. Hydra Biosciences, Inc. Recent Development Table 139. Glenmark Pharmaceuticals Ltd. Company Information Table 140. Glenmark Pharmaceuticals Ltd. Business Overview Table 141. Glenmark Pharmaceuticals Ltd. Diabetic Neuropathic Pain Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 142. Glenmark Pharmaceuticals Ltd. Diabetic Neuropathic Pain Drug Product Portfolio Table 143. Glenmark Pharmaceuticals Ltd. Recent Development Table 144. Dong-A Socio Group Company Information Table 145. Dong-A Socio Group Business Overview Table 146. Dong-A Socio Group Diabetic Neuropathic Pain Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 147. Dong-A Socio Group Diabetic Neuropathic Pain Drug Product Portfolio Table 148. Dong-A Socio Group Recent Development Table 149. Daiichi Sankyo Company, Limited Company Information Table 150. Daiichi Sankyo Company, Limited Business Overview Table 151. Daiichi Sankyo Company, Limited Diabetic Neuropathic Pain Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 152. Daiichi Sankyo Company, Limited Diabetic Neuropathic Pain Drug Product Portfolio Table 153. Daiichi Sankyo Company, Limited Recent Development Table 154. Boehringer Ingelheim GmbH Company Information Table 155. Boehringer Ingelheim GmbH Business Overview Table 156. Boehringer Ingelheim GmbH Diabetic Neuropathic Pain Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 157. Boehringer Ingelheim GmbH Diabetic Neuropathic Pain Drug Product Portfolio Table 158. Boehringer Ingelheim GmbH Recent Development Table 159. BioDelivery Sciences International, Inc. Company Information Table 160. BioDelivery Sciences International, Inc. Business Overview Table 161. BioDelivery Sciences International, Inc. Diabetic Neuropathic Pain Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 162. BioDelivery Sciences International, Inc. Diabetic Neuropathic Pain Drug Product Portfolio Table 163. BioDelivery Sciences International, Inc. Recent Development Table 164. Key Raw Materials Table 165. Raw Materials Key Suppliers Table 166. Diabetic Neuropathic Pain Drug Distributors List Table 167. Diabetic Neuropathic Pain Drug Customers List Table 168. Research Programs/Design for This Report Table 169. Authors List of This Report Table 170. Secondary Sources Table 171. Primary Sources List of Figures Figure 1. Diabetic Neuropathic Pain Drug Product Image Figure 2. Global Diabetic Neuropathic Pain Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Diabetic Neuropathic Pain Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Diabetic Neuropathic Pain Drug Sales (2021-2032) & (W Units) Figure 5. Global Diabetic Neuropathic Pain Drug Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Diabetic Neuropathic Pain Drug Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. AZD-5213 Image Figure 9. E-52862 Image Figure 10. GERPOOI Image Figure 11. GRC-17536 Image Figure 12. Filgrastim Image Figure 13. Duloxetine Hydrochloride DR Image Figure 14. Clonidine Hydrochloride Image Figure 15. Others Image Figure 16. Global Diabetic Neuropathic Pain Drug Sales by Type (2021 VS 2025 VS 2032) & (W Units) Figure 17. Global Diabetic Neuropathic Pain Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 18. Global Diabetic Neuropathic Pain Drug Sales Market Share by Type (2021-2032) Figure 19. Global Diabetic Neuropathic Pain Drug Revenue by Type (2021 VS 2025 VS 2032) & (W Units) Figure 20. Global Diabetic Neuropathic Pain Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 21. Global Diabetic Neuropathic Pain Drug Revenue Market Share by Type (2021-2032) Figure 22. Clinic Image Figure 23. Hospital Image Figure 24. Others Image Figure 25. Global Diabetic Neuropathic Pain Drug Sales by Application (2021 VS 2025 VS 2032) & (W Units) Figure 26. Global Diabetic Neuropathic Pain Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 27. Global Diabetic Neuropathic Pain Drug Sales Market Share by Application (2021-2032) Figure 28. Global Diabetic Neuropathic Pain Drug Revenue by Application (2021 VS 2025 VS 2032) & (W Units) Figure 29. Global Diabetic Neuropathic Pain Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 30. Global Diabetic Neuropathic Pain Drug Revenue Market Share by Application (2021-2032) Figure 31. North America Diabetic Neuropathic Pain Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 32. North America Diabetic Neuropathic Pain Drug Sales Market Share by Country (2021-2032) Figure 33. U.S. Diabetic Neuropathic Pain Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 34. Canada Diabetic Neuropathic Pain Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 35. Mexico Diabetic Neuropathic Pain Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 36. Europe Diabetic Neuropathic Pain Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 37. Europe Diabetic Neuropathic Pain Drug Sales Market Share by Country (2021-2032) Figure 38. Germany Diabetic Neuropathic Pain Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 39. France Diabetic Neuropathic Pain Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 40. U.K. Diabetic Neuropathic Pain Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 41. Italy Diabetic Neuropathic Pain Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 42. Netherlands Diabetic Neuropathic Pain Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 43. Asia Pacific Diabetic Neuropathic Pain Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 44. Asia Pacific Diabetic Neuropathic Pain Drug Sales Market Share by Country (2021-2032) Figure 45. China Diabetic Neuropathic Pain Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 46. Japan Diabetic Neuropathic Pain Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 47. South Korea Diabetic Neuropathic Pain Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 48. Southeast Asia Diabetic Neuropathic Pain Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 49. India Diabetic Neuropathic Pain Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 50. Australia Diabetic Neuropathic Pain Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 51. South America, Middle East and Africa Diabetic Neuropathic Pain Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 52. South America, Middle East and Africa Diabetic Neuropathic Pain Drug Sales Market Share by Country (2021-2032) Figure 53. Brazil Diabetic Neuropathic Pain Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 54. South Africa Diabetic Neuropathic Pain Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 55. Saudi Arabia Diabetic Neuropathic Pain Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 56. Turkey Diabetic Neuropathic Pain Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 57. Argentina Diabetic Neuropathic Pain Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 58. UAE Diabetic Neuropathic Pain Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 59. Egypt Diabetic Neuropathic Pain Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 60. Chile Diabetic Neuropathic Pain Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 61. Global Diabetic Neuropathic Pain Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Global Diabetic Neuropathic Pain Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 63. North America Diabetic Neuropathic Pain Drug Revenue (2021-2032) & (US$ Million) Figure 64. North America Diabetic Neuropathic Pain Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Europe Diabetic Neuropathic Pain Drug Revenue (2021-2032) & (US$ Million) Figure 66. Europe Diabetic Neuropathic Pain Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Asia-Pacific Diabetic Neuropathic Pain Drug Revenue (2021-2032) & (US$ Million) Figure 68. Asia-Pacific Diabetic Neuropathic Pain Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 69. South America, Middle East and Africa Diabetic Neuropathic Pain Drug Revenue (2021-2032) & (US$ Million) Figure 70. South America, Middle East and Africa Diabetic Neuropathic Pain Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 71. Diabetic Neuropathic Pain Drug Value Chain Figure 72. Manufacturing Cost Structure Figure 73. Diabetic Neuropathic Pain Drug Production Mode & Process Figure 74. Direct Comparison with Distribution Share Figure 75. Distributors Profiles Figure 76. Years Considered Figure 77. Research Process Figure 78. Key Executives Interviewed

Scope & coverage.

Types
  • AZD-5213
  • E-52862
  • GERPOOI
  • GRC-17536
  • Filgrastim
  • Duloxetine Hydrochloride DR
  • Clonidine Hydrochloride
  • Others
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • Eli Lilly and Company
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • Theravasc, Inc.
  • Sphaera Pharma Pvt. Ltd.
  • Relmada Therapeutics, Inc.
  • RAPID Pharmaceuticals AG
  • Pharmaleads
  • Novaremed
  • Mertiva AB
  • Lohocla Research Corporation
  • Laboratorios Del Dr. Esteve S.A.
  • Immune Pharmaceuticals Inc.
  • Hydra Biosciences, Inc.
  • Glenmark Pharmaceuticals Ltd.
  • Dong-A Socio Group
  • Daiichi Sankyo Company, Limited
  • Boehringer Ingelheim GmbH
  • BioDelivery Sciences International, Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Diabetic Neuropathic Pain Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Diabetic Neuropathic Pain Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Diabetic Neuropathic Pain Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Diabetic Neuropathic Pain Drug Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Diabetic Neuropathic Pain Drug Market Dynamics
  1. 2.1 Diabetic Neuropathic Pain Drug Industry Trends
  2. 2.2 Diabetic Neuropathic Pain Drug Industry Drivers
  3. 2.3 Diabetic Neuropathic Pain Drug Industry Opportunities and Challenges
  4. 2.4 Diabetic Neuropathic Pain Drug Industry Restraints
3 Diabetic Neuropathic Pain Drug Market by Manufacturers
  1. 3.1 Global Diabetic Neuropathic Pain Drug Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Diabetic Neuropathic Pain Drug Sales by Manufacturers (2021-2026)
  3. 3.3 Global Diabetic Neuropathic Pain Drug Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Diabetic Neuropathic Pain Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Diabetic Neuropathic Pain Drug Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Diabetic Neuropathic Pain Drug Manufacturers, Product Type & Application
  7. 3.7 Global Diabetic Neuropathic Pain Drug Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Diabetic Neuropathic Pain Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Diabetic Neuropathic Pain Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Diabetic Neuropathic Pain Drug Tier 1, Tier 2, and Tier 3
4 Diabetic Neuropathic Pain Drug Market by Type
  1. 4.1 Diabetic Neuropathic Pain Drug Type Introduction
  2. 4.1.1 AZD-5213
  3. 4.1.2 E-52862
  4. 4.1.3 GERPOOI
  5. 4.1.4 GRC-17536
  6. 4.1.5 Filgrastim
  7. 4.1.6 Duloxetine Hydrochloride DR
  8. 4.1.7 Clonidine Hydrochloride
  9. 4.1.8 Others
  10. 4.2 Global Diabetic Neuropathic Pain Drug Sales by Type
  11. 4.2.1 Global Diabetic Neuropathic Pain Drug Sales by Type (2021 VS 2025 VS 2032)
  12. 4.2.2 Global Diabetic Neuropathic Pain Drug Sales by Type (2021-2032)
  13. 4.2.3 Global Diabetic Neuropathic Pain Drug Sales Market Share by Type (2021-2032)
  14. 4.3 Global Diabetic Neuropathic Pain Drug Revenue by Type
  15. 4.3.1 Global Diabetic Neuropathic Pain Drug Revenue by Type (2021 VS 2025 VS 2032)
  16. 4.3.2 Global Diabetic Neuropathic Pain Drug Revenue by Type (2021-2032)
  17. 4.3.3 Global Diabetic Neuropathic Pain Drug Revenue Market Share by Type (2021-2032)
5 Diabetic Neuropathic Pain Drug Market by Application
  1. 5.1 Diabetic Neuropathic Pain Drug Application Introduction
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Others
  5. 5.2 Global Diabetic Neuropathic Pain Drug Sales by Application
  6. 5.2.1 Global Diabetic Neuropathic Pain Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Diabetic Neuropathic Pain Drug Sales by Application (2021-2032)
  8. 5.2.3 Global Diabetic Neuropathic Pain Drug Sales Market Share by Application (2021-2032)
  9. 5.3 Global Diabetic Neuropathic Pain Drug Revenue by Application
  10. 5.3.1 Global Diabetic Neuropathic Pain Drug Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Diabetic Neuropathic Pain Drug Revenue by Application (2021-2032)
  12. 5.3.3 Global Diabetic Neuropathic Pain Drug Revenue Market Share by Application (2021-2032)
6 Global Diabetic Neuropathic Pain Drug Sales by Region
  1. 6.1 Global Diabetic Neuropathic Pain Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Diabetic Neuropathic Pain Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Diabetic Neuropathic Pain Drug Sales by Region (2021-2026)
  4. 6.2.2 Global Diabetic Neuropathic Pain Drug Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Diabetic Neuropathic Pain Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Diabetic Neuropathic Pain Drug Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Diabetic Neuropathic Pain Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Diabetic Neuropathic Pain Drug Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Diabetic Neuropathic Pain Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Diabetic Neuropathic Pain Drug Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Diabetic Neuropathic Pain Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Diabetic Neuropathic Pain Drug Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Diabetic Neuropathic Pain Drug Revenue by Region
  1. 7.1 Global Diabetic Neuropathic Pain Drug Revenue by Region
  2. 7.1.1 Global Diabetic Neuropathic Pain Drug Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Diabetic Neuropathic Pain Drug Revenue by Region (2021-2026)
  4. 7.1.3 Global Diabetic Neuropathic Pain Drug Revenue by Region (2027-2032)
  5. 7.1.4 Global Diabetic Neuropathic Pain Drug Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Diabetic Neuropathic Pain Drug Revenue (2021-2032)
  8. 7.2.2 North America Diabetic Neuropathic Pain Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Diabetic Neuropathic Pain Drug Revenue (2021-2032)
  11. 7.3.2 Europe Diabetic Neuropathic Pain Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Diabetic Neuropathic Pain Drug Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Diabetic Neuropathic Pain Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Diabetic Neuropathic Pain Drug Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Diabetic Neuropathic Pain Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Eli Lilly and Company
  2. 8.1.1 Eli Lilly and Company Company Information
  3. 8.1.2 Eli Lilly and Company Business Overview
  4. 8.1.3 Eli Lilly and Company Diabetic Neuropathic Pain Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Eli Lilly and Company Diabetic Neuropathic Pain Drug Product Portfolio
  6. 8.1.5 Eli Lilly and Company Recent Developments
  7. 8.2 Astellas Pharma Inc.
  8. 8.2.1 Astellas Pharma Inc. Company Information
  9. 8.2.2 Astellas Pharma Inc. Business Overview
  10. 8.2.3 Astellas Pharma Inc. Diabetic Neuropathic Pain Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Astellas Pharma Inc. Diabetic Neuropathic Pain Drug Product Portfolio
  12. 8.2.5 Astellas Pharma Inc. Recent Developments
  13. 8.3 AstraZeneca Plc
  14. 8.3.1 AstraZeneca Plc Company Information
  15. 8.3.2 AstraZeneca Plc Business Overview
  16. 8.3.3 AstraZeneca Plc Diabetic Neuropathic Pain Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 AstraZeneca Plc Diabetic Neuropathic Pain Drug Product Portfolio
  18. 8.3.5 AstraZeneca Plc Recent Developments
  19. 8.4 Theravasc, Inc.
  20. 8.4.1 Theravasc, Inc. Company Information
  21. 8.4.2 Theravasc, Inc. Business Overview
  22. 8.4.3 Theravasc, Inc. Diabetic Neuropathic Pain Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Theravasc, Inc. Diabetic Neuropathic Pain Drug Product Portfolio
  24. 8.4.5 Theravasc, Inc. Recent Developments
  25. 8.5 Sphaera Pharma Pvt. Ltd.
  26. 8.5.1 Sphaera Pharma Pvt. Ltd. Company Information
  27. 8.5.2 Sphaera Pharma Pvt. Ltd. Business Overview
  28. 8.5.3 Sphaera Pharma Pvt. Ltd. Diabetic Neuropathic Pain Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Sphaera Pharma Pvt. Ltd. Diabetic Neuropathic Pain Drug Product Portfolio
  30. 8.5.5 Sphaera Pharma Pvt. Ltd. Recent Developments
  31. 8.6 Relmada Therapeutics, Inc.
  32. 8.6.1 Relmada Therapeutics, Inc. Company Information
  33. 8.6.2 Relmada Therapeutics, Inc. Business Overview
  34. 8.6.3 Relmada Therapeutics, Inc. Diabetic Neuropathic Pain Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Relmada Therapeutics, Inc. Diabetic Neuropathic Pain Drug Product Portfolio
  36. 8.6.5 Relmada Therapeutics, Inc. Recent Developments
  37. 8.7 RAPID Pharmaceuticals AG
  38. 8.7.1 RAPID Pharmaceuticals AG Company Information
  39. 8.7.2 RAPID Pharmaceuticals AG Business Overview
  40. 8.7.3 RAPID Pharmaceuticals AG Diabetic Neuropathic Pain Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 RAPID Pharmaceuticals AG Diabetic Neuropathic Pain Drug Product Portfolio
  42. 8.7.5 RAPID Pharmaceuticals AG Recent Developments
  43. 8.8 Pharmaleads
  44. 8.8.1 Pharmaleads Company Information
  45. 8.8.2 Pharmaleads Business Overview
  46. 8.8.3 Pharmaleads Diabetic Neuropathic Pain Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Pharmaleads Diabetic Neuropathic Pain Drug Product Portfolio
  48. 8.8.5 Pharmaleads Recent Developments
  49. 8.9 Novaremed
  50. 8.9.1 Novaremed Company Information
  51. 8.9.2 Novaremed Business Overview
  52. 8.9.3 Novaremed Diabetic Neuropathic Pain Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Novaremed Diabetic Neuropathic Pain Drug Product Portfolio
  54. 8.9.5 Novaremed Recent Developments
  55. 8.10 Mertiva AB
  56. 8.10.1 Mertiva AB Company Information
  57. 8.10.2 Mertiva AB Business Overview
  58. 8.10.3 Mertiva AB Diabetic Neuropathic Pain Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Mertiva AB Diabetic Neuropathic Pain Drug Product Portfolio
  60. 8.10.5 Mertiva AB Recent Developments
  61. 8.11 Lohocla Research Corporation
  62. 8.11.1 Lohocla Research Corporation Company Information
  63. 8.11.2 Lohocla Research Corporation Business Overview
  64. 8.11.3 Lohocla Research Corporation Diabetic Neuropathic Pain Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Lohocla Research Corporation Diabetic Neuropathic Pain Drug Product Portfolio
  66. 8.11.5 Lohocla Research Corporation Recent Developments
  67. 8.12 Laboratorios Del Dr. Esteve S.A.
  68. 8.12.1 Laboratorios Del Dr. Esteve S.A. Company Information
  69. 8.12.2 Laboratorios Del Dr. Esteve S.A. Business Overview
  70. 8.12.3 Laboratorios Del Dr. Esteve S.A. Diabetic Neuropathic Pain Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Laboratorios Del Dr. Esteve S.A. Diabetic Neuropathic Pain Drug Product Portfolio
  72. 8.12.5 Laboratorios Del Dr. Esteve S.A. Recent Developments
  73. 8.13 Immune Pharmaceuticals Inc.
  74. 8.13.1 Immune Pharmaceuticals Inc. Company Information
  75. 8.13.2 Immune Pharmaceuticals Inc. Business Overview
  76. 8.13.3 Immune Pharmaceuticals Inc. Diabetic Neuropathic Pain Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Immune Pharmaceuticals Inc. Diabetic Neuropathic Pain Drug Product Portfolio
  78. 8.13.5 Immune Pharmaceuticals Inc. Recent Developments
  79. 8.14 Hydra Biosciences, Inc.
  80. 8.14.1 Hydra Biosciences, Inc. Company Information
  81. 8.14.2 Hydra Biosciences, Inc. Business Overview
  82. 8.14.3 Hydra Biosciences, Inc. Diabetic Neuropathic Pain Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Hydra Biosciences, Inc. Diabetic Neuropathic Pain Drug Product Portfolio
  84. 8.14.5 Hydra Biosciences, Inc. Recent Developments
  85. 8.15 Glenmark Pharmaceuticals Ltd.
  86. 8.15.1 Glenmark Pharmaceuticals Ltd. Company Information
  87. 8.15.2 Glenmark Pharmaceuticals Ltd. Business Overview
  88. 8.15.3 Glenmark Pharmaceuticals Ltd. Diabetic Neuropathic Pain Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Glenmark Pharmaceuticals Ltd. Diabetic Neuropathic Pain Drug Product Portfolio
  90. 8.15.5 Glenmark Pharmaceuticals Ltd. Recent Developments
  91. 8.16 Dong-A Socio Group
  92. 8.16.1 Dong-A Socio Group Company Information
  93. 8.16.2 Dong-A Socio Group Business Overview
  94. 8.16.3 Dong-A Socio Group Diabetic Neuropathic Pain Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Dong-A Socio Group Diabetic Neuropathic Pain Drug Product Portfolio
  96. 8.16.5 Dong-A Socio Group Recent Developments
  97. 8.17 Daiichi Sankyo Company, Limited
  98. 8.17.1 Daiichi Sankyo Company, Limited Company Information
  99. 8.17.2 Daiichi Sankyo Company, Limited Business Overview
  100. 8.17.3 Daiichi Sankyo Company, Limited Diabetic Neuropathic Pain Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Daiichi Sankyo Company, Limited Diabetic Neuropathic Pain Drug Product Portfolio
  102. 8.17.5 Daiichi Sankyo Company, Limited Recent Developments
  103. 8.18 Boehringer Ingelheim GmbH
  104. 8.18.1 Boehringer Ingelheim GmbH Company Information
  105. 8.18.2 Boehringer Ingelheim GmbH Business Overview
  106. 8.18.3 Boehringer Ingelheim GmbH Diabetic Neuropathic Pain Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Boehringer Ingelheim GmbH Diabetic Neuropathic Pain Drug Product Portfolio
  108. 8.18.5 Boehringer Ingelheim GmbH Recent Developments
  109. 8.19 BioDelivery Sciences International, Inc.
  110. 8.19.1 BioDelivery Sciences International, Inc. Company Information
  111. 8.19.2 BioDelivery Sciences International, Inc. Business Overview
  112. 8.19.3 BioDelivery Sciences International, Inc. Diabetic Neuropathic Pain Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  113. 8.19.4 BioDelivery Sciences International, Inc. Diabetic Neuropathic Pain Drug Product Portfolio
  114. 8.19.5 BioDelivery Sciences International, Inc. Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Diabetic Neuropathic Pain Drug Value Chain Analysis
  2. 9.1.1 Diabetic Neuropathic Pain Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Diabetic Neuropathic Pain Drug Production Mode & Process
  6. 9.2 Diabetic Neuropathic Pain Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Diabetic Neuropathic Pain Drug Distributors
  9. 9.2.3 Diabetic Neuropathic Pain Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst